BPX 201

Drug Profile

BPX 201

Alternative Names: AP-1903 activated BPX 201; BPX-201; Rimiducid activated BPX 201; Second generation autologous DeCIDe vaccine (BPX-201) - Bellicum Pharmaceuticals

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal, Injection)
  • 25 Mar 2016 Bellicum completes enrolment in its phase I trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (NCT01823978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top